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We  conducted  a  meta-analysis  on the available  data  from  studies  investigating  SERTs  in ecstasy  users  and
polydrug  using  controls.  From  7  studies  we  compared  data  from  157  ecstasy  users  and  148 controls  across
14 brain  regions.  The  main  effect  suggested  ecstasy/MDMA  related  SERT  reductions  (SMD  = 0.52,  95% CIs
[0.40,  0.65];  Z  =  8.36,  p <  .01,  I2 = 89%).  A signiﬁcant  effect  of  subgroups  (X2 = 37.41,  df  =  13, p  < .01,  I2 = 65.3%)
suggested  differential  effects  across  brain  ROIs.  Ecstasy  users  showed  signiﬁcant  SERT  reductions  in  11 out
of  the  14 regions,  including  every  neocortical  and  limbic  region  analysed.  Greatest  effects  were  observed
in  the  occipital  cortex  (SMD  =  1.09,  95% CIs  [0.70,  1.48]).  No  group  effects  were  observed  in subcorticalDMA
erotonin
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eta-analysis
areas  of the  caudate,  putamen  and  midbrain.  Literature  on Postsynaptic  5HT2A receptor  imaging  was
synthesised  with  these  results.  We  conclude  that, in  line  with  preclinical  data,  serotonin  axons  with  the
longest  projections  from  the  raphe nuclei  appear  to  be most  affected  by  ecstasy/MDMA  use.
© 2016  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).olecular imaging
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. Introduction
Ecstasy (3,4-methylenedioxymethamphetamine) remains one
f the most popular illicit recreational drugs in the UK, with
 lifetime prevalence of 9.3% (EMCDDA, European Drug Report
015), and presents a major public health concern given recent
ncreases in reports of MDMA-related deaths and increasing
trength of tablets (Global Drugs Survey 2015 report tablets con-
aining upwards of 200 mg  of MDMA).
Acute effects of ecstasy/MDMA administration include increases
n energy and euphoria (Dumont and Verkes, 2006), amongst
ther psychological and physiological alterations that are primar-
ly mediated by serotonin and norepinephrine release (Hysek et al.,
011; Hysek et al., 2012). The increase in serotonin neurotransmis-
ion following MDMA  administration is understood to be produced
ia action at the serotonin transporter (SERT) (Verrico et al., 2007).
ong lasting toxic effects of MDMA  on central serotonin neurons
ave been observed in primates (Ricaurte et al., 1988) and animal
esearch has demonstrated evidence of lasting reductions in mark-
rs of central serotonin axons and axon terminals (Ricaurte and
cCann, 2001). Moreover, evidence from preclinical anatomical
tudies suggests that there is an association between axon length
nd vulnerability to neurotoxic effects of MDMA  (Molliver et al.,
990), whereby the longest axons extending from 5-HT neurons
re more susceptible to damage from MDMA.  Serotonin neurons
roject from the raphe nuclei which are situated near the midline
f the brainstem (Hornung, 2003). As such those neurons with the
ongest axons are those innervating the cortex, and are thus more
usceptible to MDMA  related neuroadaptations than those shorter
xons innervating subcortical structures (Urban et al., 2012).
It is difﬁcult to make direct comparisons between the selec-
ive serotonergic neurotoxicity observed in animal studies using
cstasy/MDMA and those using human participants. Moreover,
irect measurement of the effect of ecstasy on human brain sero-
onin axons is not possible in vivo. However molecular imaging of
arkers for presynaptic SERT and postsynaptic 5HT2A receptors is
ossible in humans using Positron Emission Tomography (PET) and
ingle Photon Emission Computed Tomography (SPECT).
Using radio-ligand neuroimaging has enabled the progression
f the study of potential ecstasy/MDMA related serotonin axon
euroadaptations. However, there has been much variation in the
eported results from molecular imaging studies with currently
bstinent (usually for at least 2 weeks prior to testing) ecstasy users
nd control groups. Inconsistencies can be observed between stud-
es in magnitude of, and regional extent of effect. It would therefore . . .  . . .  . . .  . .  .  . . . .  . . .  . .  . . .  . . . . .  . . . . .  .  . .  .  . . . .  .  . .  . . .  .  .  .  . .  . . . . .  . . . . .  .  .  .  .  . .  .  .  .  .  .  . 166
be beneﬁcial to the ﬁeld to be able to draw deﬁnitive conclusions
from the gamut of molecular imaging studies conducted in this
research area.
Different ﬁndings have been observed between studies regard-
ing susceptibility to SERT reductions in the striatum (caudate and
putamen) of ecstasy users, for example McCann et al. (2005) report
no differences between users and MDMA-naïve polydrug users
in these areas using 2 different tracers, and several other stud-
ies observe little effect on SERT in these structures (Semple et al.,
1999; Kish et al., 2010; Urban et al., 2012). However, Buchert et al.
(2003) report reduced cortical SERT Distribution Volume Ratio
(DVR) s in ecstasy users relative to polydrug controls. The thala-
mus has also been reported to show no reduction in SERT in ecstasy
users in some cases (Semple et al., 1999; Kish et al., 2010), and sig-
niﬁcantly reduced SERT relative to controls in others (Buchert et al.,
2003; McCann et al., 2005).
Cortical regions are more consistently affected, with ecstasy
users regularly showing SERT reductions in the occipital cortex
(McCann et al., 1998; McCann et al., 2005; Kish et al., 2010; Urban
et al., 2012) as well as reports of increased postsynaptic 5-HT2A
receptor binding (Reneman et al., 2000). However not all regions
show this consistency. Furthermore, some analyses report signif-
icant reductions in global SERT (McCann et al., 1998) for ecstasy
users compared to controls, whereas others report more selective
regional SERT reductions (McCann et al., 2005; Kish et al., 2010),
potentially due to a highly heterogeneous distribution of SERT in
the human brain (Kish et al., 2005).
Most studies in these populations suggest that ecstasy use does
have some effect on serotonin. However, the regional distribution
and magnitude of these effects remain unknown. It is understood
that differences in radioligands may  contribute to some of the
inconsistencies in the literature. For example [123I]ßCIT—is not
SERT speciﬁc and [11C]McN5652 has been criticised for having a
modest speciﬁc to non-speciﬁc binding ratio (Heinz and Jones,
2000; Kish et al., 2010; Kuikka and Ahonen, 1999). Equally, dif-
ferences in drug use history will always vary from study to study
and are likely to inﬂuence ﬁndings, particularly as dose is inversely
correlated with SERT (McCann et al., 2005). However, potentially
the biggest problem for reporting consistent effects in this area is
due to many molecular imaging studies having small samples.
Therefore, the aim of the current study was to meta-analyse
the available data from molecular imaging studies on the central
serotonin markers of presynaptic SERT and postsynaptic 5-HT2A
receptor availability, in current (but abstinent at time of testing)
ecstasy users and non-user controls. The overall aim was  to observe
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hether ecstasy/MDMA use has an effect on SERT and 5-HT2A
eceptor availability, and to provide a comprehensive and consis-
ent understanding and synthesis of the available literature on the
ffects of MDMA/ecstasy on human brain serotonin function.
. Methods
.1. Eligibility criteria
.1.1. Participants
We  included studies that conducted molecular imaging of sero-
onin transporters (using PET or SPECT) in human ecstasy/MDMA
sing participants aged over 18 years, who did not have a history
f major psychiatric or neurological problems and were abstinent
rom drug use at the time of testing.
.1.2. Studies
Studies that conducted molecular imaging of serotonin trans-
orters (using PET or SPECT) and reported molecular imaging
utcomes relating to cerebral serotonin transporter binding
presynaptic SERT) and/or cerebral serotonin receptor binding
postsynaptic 5HT2A receptors), using Positron Emission Tomog-
aphy (PET) or Single Photon Emission Computed Tomography
SPECT) were eligible for inclusion in the meta-analysis..1.3. Comparator groups and study design
To be eligible for inclusion, all studies were required to have
n ecstasy/MDMA using condition (current users) which was com-
328 Publi caons idenﬁed from datab ase 
searches
211 stud ies idenﬁed for tle and  abstract 
screening
166  ar
(revie
admin
using 
45 stud ies eli gible for full  text review.
Review  reﬁned to outcomes relang to 
pre-synapc SERT and /or post-synap c 
5HT2A receptors
(Not cu
me
longit
15 arcles Idenﬁed for inclusion from 
electronic searches.
10 arcles includ ed in ﬁnal review, 7 
includ ed in Meta -Analysis
6 arcl
Fig. 1. Meta-analysis search ehavioral Reviews 63 (2016) 158–167
pared to at least one form of control/comparison group, in a
between subjects design.
2.1.4. Outcome measure
SPECT and PET studies investigating SERT and 5HT2A receptor
binding can have a range of outcome measures. These include the
simple ratio of binding in a particular region of interest in compari-
son to a non-binding reference region (Speciﬁc Uptake Ratio—SUR).
Binding potential (BPND) may also be calculated when dynamic
emission sequences are available, which gives the reader informa-
tion about speciﬁc binding relative to reference tissue. V3” refers
to the speciﬁc to non-displaceable equilibrium partition and DVR
refers to an outcome that is associated with the equilibrium of the
tracer in the brain, which is reported when arterial input function
is measured (Gryglewski et al., 2014).
2.2. Data search and extraction
2.2.1. Information sources and search strategy
For the formal search strategy, 3 electronic databases were
searched during April 2015. These were: PsychINFO, Scopus and
Web of Science. Systematic searches used the key terms ‘Ecstasy’
OR ‘MDMA’ AND, ‘PET’ OR ‘SPECT’ OR ‘molecular imaging’. Manual
searches of the reference sections of identiﬁed articles and relevant
sources were also conducted to supplement the formal electronic
search. Further to this, supplementary electronic searches of the
3 databases previously used were undertaken prior to publication
with no further articles identiﬁed.
117 publi caons removed du e to dupli caon
cles removed du e to irr elevance to curr ent analysis 
w arcles or comm entari es,  non-hu man  stud ies,  acute 
istraon stud ies, other sub stance stud ies,  or not 
molecular imaging)
30 arcles removed du e to ineli gibility
rr ent users,  5-HT synthesis cap acity , cerebral glucose 
tab oli sm, cerebral bloo d ﬂow. Prospecve stud ies,  
ud inal stud ies,  dupli caon, revalua on of previously 
reported data)
es exclud ed du e to un obtainable da ta, 1 arcle add ed 
during review process
results and ﬂow chart.
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.2.2. Article selection and extraction of data
Independent searches of the electronic databases were carried
ut by two authors (CR and CM). Both authors were responsible
or assessment of articles for inclusion in analysis, with any dis-
greements resolved by discussion. One author (CR) extracted the
elevant data from the studies, which was cross-checked by a sec-
nd author (CM). In cases where a study met  the inclusion criteria
ut insufﬁcient information was provided to compute the effect
ize, data was requested from the corresponding author of the
aper. Data requests were not met  for 6 articles (Reneman et al.,
001a,b; Thomasius et al., 2003; Buchert et al., 2004; de Win  et al.,
004, 2008). Therefore, analyses were conducted on data from 7
ublications (Fig. 1).
.2.3. Additional handling of data
Means and Standard Deviations (SDs) were estimated from the
gure presented in McCann et al. (1998), using Web  Plot Digitizer
.8 (Rohatgi, 2015). Data presented in Semple et al. (1999) provided
eparate means and SDs for the left and right side of each brain
egion measured; for inclusion of this data in the current analysis
he authors transformed this data into a mean value for each brain
egion by combining the mean values for left and right and dividing
y 2. The same procedure was used for transforming the SDs.
.2.4. Data items extracted for individual studies
The following data were extracted from the published articles
or analysis separately for each group of participants: outcome for
ach region reported, age, estimated lifetime dose of ecstasy, time
ince last use, type of tracer, type of outcome measure, number
f participants in group and gender split (Table 1). These vari-
bles were recorded in the form they were originally presented.
n cases where mean abstinence duration from ecstasy was not
eported, minimum abstinence required for inclusion in the study
as recorded. In cases where mean lifetime doses of ecstasy use
ere not reported, an estimate was calculated if possible from
he data available, for example McCann et al., 2005 report usual
ose and lifetime exposures, in cases such as this an estimate life-
ime dose was calculated by multiplying these values. Ecstasy user
roups could broadly be deﬁned by two categories (current users,
ormer users). Control groups would also generally fall within 3 cat-
gories, for example “polydrug controls” refers to groups that were
DMA  naïve but were recruited due to them having some degree
f matching for use of other drugs. ‘Controls with some polydrug
se’ refers to groups who were not recruited explicitly due to them
aving used illicit drugs, yet use of illicit drugs had not resulted in
xclusion of participants. Drug naïve controls generally allowed for
se of legally available drugs such as nicotine and alcohol.
.3. Statistical and subgroup analysis
Standardised Mean Difference (SMD) and Standard Error (SE)
f the SMD  between experimental conditions were calculated sep-
rately for reported brain regions in each study. Individual SMDs
ere synthesised by meta-analysis using the method of generic
nverse variance (random effects assumed) in the software pack-
ge RevMan 5.2 (The Nordic Cochrane Centre, Copenhagen). The
agnitude of effects of SMDs can be interpreted thus: 0.2 = a small
ffect, 0.5 = a moderate effect and 0.8 = a large effect (Higgins and
reen, 2011) SMDs were employed due to the main outcomes of
nterest in PET and SPECT studies on SERT binding and serotonin
eceptor binding having several possible outcome measures.SMD  allows for variation in outcome measures, by estimating
he differences between 2 experimental conditions on an outcome
ariable, and dividing the difference by the pooled SDs of the out-
ome variable. Ta
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Table 2
Meta-analysis summary table by brain region.
Region Studies Total n SMD  p from Meta-Analysis
Frontal Cortex 3 148 (73 ecstasy users) 0.54 0.002
Midbrain 5 246 (117 ecstasy users) 0.13 0.36
Parietal  Cortex 4 196 (99 ecstasy users) 0.97 0.0003
Temporal Cortex 4 196 (99 ecstasy users) 0.94 <0.00001
Occipital Cortex 5 216 (109 ecstasy users) 1.09 <0.00001
Caudate  6 275 (139 ecstasy users) 0.19 0.15
Putamen 6 275 (139 ecstasy users) 0.22 0.11
Thalamus 6 275 (139 ecstasy users) 0.31 0.002
Anterior Cingulate 4 187 (95 ecstasy users) 0.48 0.0001
Hippocampus 3 167 (85 ecstasy users) 0.57 0.006
DLPFC  2 68 (36 ecstasy users) 0.83 0.02
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.3.1. Analytic strategy
The meta-analysis was conducted by separating effect sizes
rom each study into brain regions, as speciﬁed in individual
tudies. We  examined the main effect and also formal subgroup
nalyses, whereby each brain region appraised in 2 or more studies
as considered a sub-group. This main analysis was conducted on
he 7 articles that investigated SERT availability and was  a compar-
son of current ecstasy users binding vs polydrug controls/controls
ith some polydrug use. One study (Urban et al., 2012) reported
oth presynaptic SERT binding and postsynaptic 5HT2A receptor
inding, as such the 10 papers yielded 7 that were suitable for SERT
inding comparison and 4 that were eligible for postsynaptic 5HT2A
eceptor binding assessment. Due to the low number of articles eli-
ible for postsynaptic 5HT2A receptor analysis, and differences in
rain regions investigated, we provide a narrative synthesis rather
han formal analysis of these studies.
One publication (McCann et al., 2005) conducted SERT bind-
ng analysis using 2 different tracers, within the same sample—as
uch, only data using the tracer [11C]DASB is included in the meta-
nalysis. This choice is based upon [11C]DASB having important
dvantages over [11C]McN5652 in detecting SERT density, namely,
 greater speciﬁc-to-nonspeciﬁc equilibrium activity ratio (McCann
t al., 2005). A high correlation between the two tracers (r = 0.97)
ustiﬁed inclusion of only [11C]DASB. Most studies included 2 con-
itions and as such potentially contributed one comparison per
rain region to main analysis. Moreover, from the 7 studies deemed
cceptable for analysis of SERTs, it was noted that only one of these
Buchert et al., 2003) employed a drug naïve control group (and also
 former ecstasy user group). However, this study also employed
 polydrug control group. Therefore, it was decided, that analysis
hould focus on control groups that had some drug use (polydrug
ontrols and controls with some polydrug use). Consequently, all
etween group comparisons in the main meta-analysis have some
egree of matching for use of other drugs. This controls for con-
omitant use of other drugs, which is regularly reported in the
iterature in this area. We  conducted random effects models due
o high heterogeneity across studies.
. Results
.1. Study selection
Initial literature searches yielded 80 papers in the Scopus
atabase, 41 papers in PsychINFO and 207 papers from Web  of
cience. After removing duplicated papers a total of 211 papers
emained. Following a brief review of the remaining articles’ titles
nd abstracts, a further 166 were excluded as they were not rel-
vant to the current analysis. Excluded papers included review
rticles or commentaries (32), non-human studies (68), acutey users) 0.80 0.03
y users) 0.35 0.01
sy users) 0.62 0.06
administration studies (10), other substance/not serotonin studies
(16), no use of molecular imaging (24), non-substance popula-
tions (12) and case studies (4). Following this 45 full articles were
reviewed. Studies were removed at this stage if they did not have
a control group or did not have a current user group, investigated
serotonin synthesis capacity or cerebral glucose metabolism and
cerebral blood ﬂow. Prospective studies on novice ecstasy users,
as well as longitudinal studies using a within groups design were
also excluded at this stage. Following adherence to these exclusion
criteria, 15 studies remained. Due to unavailable data in 6 studies,
and a further eligible study identiﬁed during the review process
ﬁnal assessment was  conducted on data from 10 publications (7
contributing data to the meta-analysis).
3.2. Overview
3.2.1. Participant characteristics
Individual study information including sample sizes and partic-
ipant characteristics are given in Table 1.
3.3. Pre synaptic SERT meta-analysis
Data from 7 published studies (Table 1) were included in analy-
ses of presynaptic SERT binding. From these there was a total of 157
ecstasy/MDMA users (7 studies), 19 polydrug controls (2 studies),
129 controls with some polydrug use (5 studies) and 29 drug naïve
controls (1 study). One study also included a former ecstasy/MDMA
sample, which provided a total of 29 participants.
3.3.1. Meta-analyses
Included studies examining presynaptic SERT binding in ecstasy
users vs polydrug/controls with some polydrug use had investi-
gated various ROIs. Each brain region that was investigated by 2
or more studies was identiﬁed as a subgroup for meta-analysis.
The test for overall effect was signiﬁcant (SMD = 0.52, 95% CIs
[0.40, 0.65]; Z = 8.36, p < .01, I2 = 89%) which demonstrated signiﬁ-
cant SERT reductions ecstasy users versus polydrug using controls.
There was  also a signiﬁcant effect of subgroups (X2 = 37.41, df = 13,
p < .01, I2 = 65.3%) suggesting differential effects across brain ROI
(Fig. 2 and Table 2). Individual analyses are reported below.
3.3.2. Frontal cortex
Three studies with a total of 73 ecstasy users and 75 controlsassessed SERT binding in the frontal cortex. A signiﬁcant difference
was observed between the two comparison groups (SMD = 0.54,
95% CIs [0.19, 0.89]; Z = 3.04, p < .01; I2 = 71%), suggesting SERT
reductions in ecstasy users relative to controls.
Carl.A. Roberts et al. / Neuroscience and Biob
Fig. 2. Forest plot of studies assessing SERT by brain region. I2 is an indicator of
heterogeneity between comparisons. Inverse variance meta-analysis using stan-
dardized mean differences.ehavioral Reviews 63 (2016) 158–167 163
3.3.3. Midbrain
There were 5 studies that assessed SERT in the midbrain, with
a total of 117 ecstasy users and 129 controls. No signiﬁcant dif-
ference in SERT was  observed between groups in this brain region
(SMD = 0.13, 95% CIs [−0.15, 0.40]; Z = 0.91, p > .05; I2 = 77%).
3.3.4. Parietal cortex
Four studies reported SERT values in the parietal cortex, there
were 99 ecstasy users in total and 97 controls. There was  a signif-
icant between group difference in this region (SMD = 0.97, 95% CIs
[0.44, 1.49]; Z = 3.61, p < .01; I2 = 91%). Ecstasy users display reduced
SERT relative to controls here.
3.3.5. Temporal cortex
Four studies assessed SERT in the temporal cortex, with a total
of 99 ecstasy users compared to 97 controls. Analysis in this area
showed a signiﬁcant difference (SMD = 0.94, 95% CIs [0.56, 1.31];
Z = 4.86, p < .01; I2 = 84%), with ecstasy users displaying reduced
SERT relative to controls.
3.3.6. Occipital cortex
Five studies gave SERT values in the occipital cortex. One
hundred and nine ecstasy users were compared to 107 controls.
Again, there were signiﬁcant differences between the two groups
(SMD = 1.09, 95% CIs [0.70, 1.48]; Z = 5.45, p < .01; I2 = 87%) which
reﬂect reduced SERT in ecstasy users compared to controls.
3.3.7. Caudate
Six studies investigated SERT in the caudate, providing a total of
139 ecstasy users and 136 controls. The difference between groups
in this region was non-signiﬁcant (SMD = 0.19, 95% CIs [−0.07,
0.45]; Z = 1.43, p > .05; I2 = 77%).
3.3.8. Putamen
Six studies assessed SERT in the putamen (139 ecstasy users
vs 136 controls), and again no differences were observed between
groups in the meta-analysis (SMD = 0.22, 95% CIs [−0.05, 0.49];
Z = 1.59, p > .05; I2 = 79%).
3.3.9. Thalamus
Six studies were included in analysis of SERT in the thalamus,
giving a total of 139 ecstasy users and 136 controls. Analysis showed
that there were signiﬁcant between group differences in the tha-
lamus (SMD = 0.31, 95% CIs [0.11, 0.51]; Z = 3.10, p < .01; I2 = 59%),
whereby ecstasy users have reduced SERT relative to controls.
3.3.10. Anterior cingulate
A total of 4 studies assessed SERT in the anterior cingu-
late, totalling 95 ecstasy users versus 92 controls. The difference
between these groups was statistically signiﬁcant (SMD = 0.48, 95%
CIs [0.26, 0.71]; Z = 4.15, p < .01; I2 = 53%), again ecstasy users have
reduced SERT relative to controls.
3.3.11. Hippocampus
Three studies reported SERT comparisons in the hippocam-
pus (total n = 85 ecstasy users, 82 controls). Differences in SERT
were signiﬁcant (SMD = 0.57, 95% CIs [0.17, 0.98]; Z = 2.76, p < .01;
I2 = 83%) with ecstasy users displaying reduced SERT here compared
to controls.
3.3.12. DLPFC
Two  studies were included in analysis of DLPFC SERT, with atotal of 36 ecstasy users and 32 controls. The difference in SERT in
the DLPFC between users and controls was statistically signiﬁcant
(SMD = 0.83, 95% CIs [0.13, 1.53]; Z = 2.33, p < .01; I2 = 88%)
whereby ecstasy users show reduced SERT.
1 d Biobehavioral Reviews 63 (2016) 158–167
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Table 3
Ranked (from highest to lowest) regional distribution volumes of SERT (as per Parsey
et  al., 2006) and 5-HT2A receptors (as per Adams et al., 2004).
SERT 5-HT2A
Midbrain Superior medial frontal cortex
Ventral striatum Occipital cortex
Thalamus Dorsolateral prefrontal cortex
Dorsal putamen Ventral lateral prefrontal cortex
Dorsal caudate Parietal cortex
Insula Superior temporal cortex
Hippocampus Orbito-frontal cortex
Cingulate Medial inferior temporal cortex
Anterior cingulate Sensory motor cortex
Temporal lobe Anterior cingulate gyrus
Medial prefrontal cortex Insula
Occipital lobe Putamen/pilladus
Orbital prefrontal cortex Thalamus64 Carl.A. Roberts et al. / Neuroscience an
.3.13. Posterior cingulate
Two studies were used to evaluate SERT in the posterior cin-
ulate, providing a total of 33 ecstasy users and 29 controls. The
eta-analysis revealed a signiﬁcant between group difference here
SMD = 0.80, 95% CIs [0.07, 1.52]; Z = 2.16, p < .05; I2 = 87%) again
cstasy users display reduced SERT compared to controls here.
.3.14. Amygdala
Two studies were entered into the meta-analysis for comparison
f SERT in the amygdala, providing a total of 36 ecstasy users and
2 controls. This analysis showed a signiﬁcant difference between
he two groups (SMD = 0.35, 95% CIs [0.08, 0.62]; Z = 2.54, p = .01;
2 = 20%). Ecstasy users show reduced SERT in the amygdala.
.3.15. Insula
Two studies had available data for analysis of SERT in the insula,
hese provided a total of 62 participants in the ecstasy user group
nd 63 participants in the control group. The difference between
hese two groups was approaching signiﬁcance (SMD = 0.62, 95%
Is [−0.02, 1.26]; Z = 1.90, p = .06; I2 = 89%), again ecstasy users show
educed SERT in the insula relative to controls.
.4. Evidence of publication bias
Visual examination of a funnel plot suggested asymmetry in
tudy effects. Funnel plot asymmetry is often associated with pub-
ication bias (Light and Pillemer, 1984), which is something often
eported as problematic in research into ecstasy related harm (Cole,
014). However, interpretation of asymmetry may  be difﬁcult due
o a number of issues including small sample sizes (Stern and
arbord, 2004), such as those observed in many types of imaging
tudies, including those involved in the current analysis and high
eterogeneity.
In order to further examine any potential publication bias and
mall study effects we performed a test for an excess of signiﬁcant
ndings (Ioannidis and Trikalonis, 2007). We estimated the average
tatistical power for all the effect sizes used in our analysis based on
he ﬁxed-effects point estimate separately for each region (overall
tatistical power = 46.48%). Based on this level of power we would
xpect 25.09 of the 54 effect sizes in the meta-analysis to be signif-
cant, yet the observed number of effect sizes that were signiﬁcant
as 34. The difference between observed and expected was beyond
hance (p = 0.08, two-sided), thus there was an excess of observed
igniﬁcant ﬁndings in the meta-analysis which may  be attributable
o publication bias.
.5. Post-synaptic 5HT2A receptor binding
The systematic literature search process yielded 4 papers for
nalysis of 5HT2A receptor binding. One of these assessed both
resynaptic SERT and post-synaptic 5HT2A binding, using PET and
o was assessed in the main meta-analysis above. However, as
here were only 4 papers assessing postsynaptic binding matching
ur review criteria, two studies using a drug naïve control group
Reneman et al., 2000, 2002), one using a control group with some
olydrug use (Urban et al., 2012) and one assessing a polydrug
omparison group (Di Iorio et al., 2012), there was little scope for
omparison groups. Adding to this complication is that there was
ittle consistency between studies in brain regions identiﬁed for
omparison. As such a formal meta-analysis was inappropriate for
cstasy users versus controls in postsynaptic 5HT2A receptor bind-
ng. Nevertheless, the data from these studies is reviewed here and
ynthesised with the ﬁndings from the meta-analysis. For regional
istribution volumes of SERT and 5-HT2A receptors see Table 3.
Reneman et al. (2000) studied cortical 5-HT2A receptor densities
n ﬁve currently abstinent MDMA  users compared to 9 healthy ageDorsolateral prefrontal cortex Caudate nucleus
Cerebellar grey matter Amygdala/hippocampus
and education matched control subjects. It was  observed that over-
all binding ratios were higher in the MDMA group than controls and
this difference was  statistically signiﬁcant in the occipital cortex.
The authors suggest that this increase in receptors is a result of 5-HT
depletion, as this leads to upregulation of 5-HT2A receptors in ani-
mal  studies in an attempt to maintain homeostasis. They also cite
their ﬁnding in the occipital cortex to be in line with work show-
ing severe MDMA  related 5-HT depletion in the occipital cortex in
primates (Scheffel et al., 1998). This ﬁnding is intriguing, given that
in the current meta-analysis ecstasy/MDMA related reductions in
SERT showed the greatest effect in the occipital cortex (SMD = 1.09).
So this area is potentially particularly sensitive to ecstasy/MDMA
induced neurotoxicity. However it is acknowledged by Reneman
and colleagues that their study has a small sample and thus should
be treated as pilot data.
More recently Urban et al. (2012) investigated neocortical post-
synaptic 5-HT2A receptor integrity in 13 current and recently
detoxiﬁed MDMA  users and 13 age, ethnicity and gender matched
healthy controls. Individual region analysis revealed signiﬁcant
increase in 5-HT2A receptor binding in ecstasy users compared to
controls in the DLPFC and in the parietal cortex. However these
did not survive correction for multiple comparisons. There were
no observed correlations between 5-HT2A receptor availability and
clinical parameters of ecstasy use history (e.g. time since last use).
As in the former studies, the authors suggest that 5-HT2A receptor
upregulation is a possible response to sustained 5-HT depletion. It is
observed that higher binding was  observed in the neocortex, where
SERT density is lower in this study (SERTs were also analysed by
Urban et al. and this data is included in the current meta-analysis).
Indeed cortical regions display consistent SERT reductions in the
current meta-analysis in ecstasy users compared to controls.
Finally, Di Iorio et al. (2012) assessed 5-HT2A receptor binding
in 14 female MDMA  users, who  had a minimum of 2 weeks drug
abstinence prior to scanning and 10 female non-MDMA exposed
controls who  had some cannabis and alcohol exposure. The great-
est difference was  reported in the temporal cluster, whereby
MDMA  users had 20.5% higher binding than controls. A further
interesting ﬁnding was  that lifetime MDMA  dose was  positively
and signiﬁcantly correlated with receptor binding in 4 cortical
clusters (frontoparietal, occipitotemporal, frontolimbic and frontal
regions). Di Iorio et al. (2012) suggest their results extend those of
Reneman et al. (2000) to multiple cortical regions and show a lack
of recovery with extended abstinence and a dose-response effect.
However this is a female only cohort, and is another study that has
a small sample size.
In line with a lack of recovery, Reneman et al. (2002) observed
signiﬁcantly higher 5-HT2A binding in 7 ex MDMA  users (min
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f 2 months abstinence), compared to 11 drug naïve controls in
he occipital cortex using [123I]R91150 SPECT. Moreover, a signif-
cant correlation was observed between cortical 5-HT2A receptor
inding and duration of abstinence, but not with lifetime dose
f MDMA.  Conversely, recent MDMA  users (n = 17 min  abstinence
 week) had lower [123I]R91150 binding ratios than controls in
ll cortical regions examined (frontal, parietal and occipital cor-
ices). Reneman et al. (2002) suggest that MDMA  use results in a
ub-chronic down regulation of 5-HT2A receptors, and a chronic
p-regulation compensating for low synaptic 5-HT. In the context
f the other work reported here on post synaptic 5-HT2A receptor
inding, these ﬁndings suggest that 5-HT2A receptor adaptations in
cstasy users are very complex and thus interpretation of ﬁndings
equires caution.
The overall ﬁndings from the post-synaptic 5-HT2A receptor
inding can be synthesised with the ﬁndings from the meta-
nalysis to suggest that MDMA  may  have an effect on serotonin
ystem function. Indeed, postsynaptic receptor levels seem to show
ess of an effect in subcortical regions. This is also analogous to
ubcortical regions (putamen, caudate, midbrain) showing no dif-
erence between users and controls in the meta-analysis. Many of
he studies on receptor binding have small numbers and so may  be
riticised for being unreliable. However the studies reviewed here,
ppear to corroborate the ﬁndings of MDMA  related adaptations to
ortical SERT in ecstasy users subject to meta-analysis.
. Discussion
The results from this meta-analysis demonstrated signiﬁcant
eductions in pre-synaptic SERT availability in ecstasy/MDMA users
ersus controls. Our subgroup analysis on different ROIs demon-
trated signiﬁcant reductions in brain regions including: the frontal
ortex, parietal cortex, temporal cortex, occipital cortex and dor-
olateral prefrontal cortex, anterior cingulate, posterior cingulate,
ippocampus, amygdala, insula and the thalamus. The overall effect
ize was moderate with large heterogeneity. However the subgroup
nalysis was also signiﬁcant, suggesting that differences in effect
ize between groups varied by subgroup (brain region), which sug-
ests that not all regions that were analysed showed the effect of
cstasy related SERT reduction.
The systematic literature search produced 7 published articles,
ith available data, for inclusion in a meta-analysis of presynaptic
ERT availability in ecstasy users compared to an MDMA,  but not
rug naïve control sample. Data from a total of 157 ecstasy users,
nd 148 controls was included in analysis, suggesting mean group
izes of 22 and 21 respectively per imaging study. Although these
re typical molecular imaging study sample sizes, it is understand-
ble that detection of small group differences has been unreliable
n the literature (Gryglewski et al., 2014). To this end this meta-
nalysis has successfully synthesised results from studies assessing
ERT availability and the results are therefore more conclusive than
ndividual reports.
Each brain region included in the analysis that could be
escribed as being in the neocortex produced a signiﬁcant differ-
nce between groups, whereby ecstasy users displayed reduced
ERT compared to controls (frontal cortex, parietal cortex, tem-
oral cortex, occipital cortex and dorsolateral prefrontal cortex).
he greatest effect was observed in the occipital cortex, which is
nsurprising as this has regularly been reported as an area of signif-
cance for reduced SERT in ecstasy users(McCann et al., 1998, 2005;
ish et al., 2010; Urban et al., 2012) as well as postsynaptic 5-HT2A
eceptor binding (Reneman et al., 2000). It is worthy of note that 4
f these neocortical areas (occipital cortex, parietal cortex, tempo-
al cortex and DLPFC) are the 4 regions showing the greatest effect
izes in the whole analysis. This is consistent with the preclinicalehavioral Reviews 63 (2016) 158–167 165
research suggesting that axon length is associated with greater vul-
nerability to neuroadaptations with MDMA  (Molliver et al., 1990).
Moreover it is interesting that studies that isolated the DLPFC have
a greater effect size than those that considered the frontal cortex
as a region of interest, as this is in line with ﬁndings of Urban et al.
(2012) who suggest that even within cortical regions, differences
can be observed with dorsal regions, which are associated with
longer axon lengths showing greater effects than medial regions.
Neuroadaptation in the DLPFC is also consistent with behavioural
data, suggesting that executive functioning is impaired in ecstasy
users relative to controls (e.g. Montgomery et al., 2005) and recent
functional Near-Infrared Spectroscopy research suggesting alter-
ation to blood ﬂow in the DLPFC of ecstasy users relative to controls
(Roberts and Montgomery, 2015).
Similarly, all regions analysed that could be categorised as mak-
ing up part of the limbic system showed signiﬁcant differences
between groups in the current analysis (anterior cingulate, poste-
rior cingulate, hippocampus, amygdala, insula). These regions are
not covered in detail in the postsynaptic 5-HT2A receptor imag-
ing literature as they are only examined in Urban et al. (2012),
who observed no signiﬁcant differences between users and con-
trols. However the same pattern of results was observed in the
same paper’s SERT data, which is included in the meta-analysis.
Furthermore, 5 of the 6 papers that data were not available for, did
not examine any limbic areas (Reneman et al., 2001a,b; Thomasius
et al., 2003; de Win  et al., 2004, 2008), whereas one paper (Buchert
et al., 2004) observed MDMA  related SERT reductions in the poste-
rior cingulate and the hippocampus, which is consistent with the
ﬁndings of the meta-analysis.
Conversely, to the neocortex and the limbic areas, the thalamus
was the only subcortical region that showed signiﬁcant between
group differences. No differences were observed between ecstasy
users and controls in the caudate, putamen (striatal cortex) or the
midbrain. These, ﬁndings from the meta-analysis are interesting if
they are placed alongside the papers that were omitted from anal-
ysis due to unavailable data. Indeed Buchert et al. (2004) suggest
reductions in the left caudate in current ecstasy users relative to
controls and Thomasius et al. (2003) also observed reduced SERT
availability in the caudate nucleus of current ecstasy users. These
ﬁndings suggest that the results on subcortical areas may  not be
as decisive as the meta-analysis concludes. However data from
these studies was not made available for inclusion. Nevertheless
the current authors assume the ﬁndings from the current analysis
to be robust given the amount of studies included. Moreover, there
is a good theoretical basis to expect that SERT rich areas such as
the striatum may  not show large reductions relative to controls.
As mentioned previously preclinical data suggest that longer axon
projections from serotonin neurons may  be more susceptible to
MDMA  related damage than shorter projections (Molliver et al.,
1990). Therefore, because the caudate, putamen and midbrain are
relatively close to the raphe nuclei, they may  be more robust to
the damaging effects of MDMA  on their axons. This is supported by
animal models of MDMA  related neurotoxicity, whereby serotoner-
gic neural regeneration is selective for centrally located neuronal
structures (Fischer et al., 1995).
While this meta-analysis shows clear evidence of neuroadapta-
tion following ecstasy use, it cannot provide conﬁrmation regarding
regeneration or reversibility of MDMA  related effects on central
serotonin axons. PET scans using [11C]DASB were conducted in for-
mer  MDMA  users with at least 1 year abstinence (Selvaraj et al.,
2009) to observe whether SERT availability could normalise over
time. It was reported that former users showed normal SERT as
compared to polydrug and drug naïve controls. However, this study
did not incorporate a current user group into analysis, and therefore
the results need to be treated with caution. Perhaps well designed
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ongitudinal studies would be better able to answer questions about
he reversibility of the effects captured in our meta-analysis.
There are several limitations to the current analysis. First of all,
s we were limited to results from 7 studies, it is of course possible
hat data that was unavailable to us at the time of analysis could
lter the current ﬁndings. The studies identiﬁed generally had low
tatistical power (see above) and together provided a small num-
er of estimates for some ROIs. Therefore, well powered studies
xamining all ROIs are required to conﬁrm the ﬁndings reported.
urthermore, due to the limited number of studies, it was  not
ppropriate to conduct a meta-regression, in which correlations
etween drug use (lifetime dose, recency of use, frequency of use)
nd SERTs could be observed. However there are several reports of
ERT binding correlating signiﬁcantly with lifetime dose and years
f use (Thomasius et al., 2003; Buchert et al., 2004; McCann et al.,
005; Kish et al., 2010).
Concomitant use of other drugs is regularly identiﬁed as a con-
ounding factor in research in ecstasy users. It is often argued that
se of other drugs is at least partly responsible for effects seen
n ecstasy using populations. It is for this reason that the deci-
ion was taken to conduct analysis on ecstasy users compared to
ontrols that are at least matched in some way for use of other
rugs. Furthermore, radiotracers used in studies included in this
eta-analysis, should have a reasonable selectivity for SERTs. Other
o-used drugs are not known for their effects on 5-HT, for exam-
le alcohol use is not associated with SERT alterations in humans
Martinez et al., 2009) and cannabis and cocaine are not known for
oxic effects on 5-HT axons. Moreover polydrug users have often
een observed to show no differences in SERT binding compared to
rug naïve controls (Buchert et al., 2004; Selvaraj et al., 2009).
Many of the studies included in the current analysis used small
amples, which is potentially a reason for the asymmetrical fun-
el plot observed with the data. However small samples can also
ead to concerns over the reliability of the data. Reliability concerns
nd variability in effects of ecstasy/MDMA on SERT and 5-HT2A
eceptors from molecular imaging studies suggested that a meta-
nalysis was necessary, using all of the available data, so to draw
ore concrete conclusions about ecstasy/MDMA related serotoner-
ic neuroadaptations.
Finally, concerns have been raised about the reliability of -CIT-
PECT and [11C]McN-5652 for detecting neocortical SERT density
Heinz and Jones, 2000; Parsey et al., 2000). These areas have com-
aratively low densities of SERT relative to subcortical regions and
hus have a worse signal-to-noise ratio. Moreover, these two radio
racers, whilst showing SERT speciﬁc binding in the brainstem and
halamus, do not show SERT speciﬁc binding in the cerebral cortex.
s such, the reliability of some of the early work in this area using
hese radio-ligands need interpreting with caution. Moreover, 3
riginal articles included in the current analysis used these less reli-
ble radio-ligands, and is therefore a limitation for interpretation
f the current analysis.
To conclude, our meta-analytic investigation suggests that SERT
vailability is reduced signiﬁcantly in current ecstasy users relative
o polydrug controls/controls with some polydrug use in all areas of
he neocortex and limbic system, with areas requiring longer axon
rojection being most vulnerable to toxicity. The meta-analysis also
uggests that SERT rich regions of the subcortex (putamen, caudate
nd midbrain) are unaffected by ecstasy use. Review of the post-
ynaptic 5-HT2A receptor data suggests that there may  also be some
ompensatory upregulation of receptors in neocortical areas. The
linical signiﬁcance of these ﬁndings is speculative, however it is
onceivable that the observed effects of SERT and 5-HT2A recep-
ors contribute to mood disorders associated with ecstasy/MDMA
se, as well as other psychobiological sequelae, such as altered
euroendocrine function. Furthermore the observed effects on theehavioral Reviews 63 (2016) 158–167
serotonin system inferred from the current analysis, may underpin
the many neurocognitive deﬁcits observed in ecstasy users.
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